These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2369744)

  • 1. Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole.
    Braunschweiger PG; Kumar N; Constantinidis I; Wehrle JP; Glickson JD; Johnson CS; Furmanski P
    Cancer Res; 1990 Aug; 50(15):4709-17. PubMed ID: 2369744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
    Braunschweiger PG; Jones SA; Johnson CS; Furmanski P
    Cancer Res; 1991 Oct; 51(20):5454-60. PubMed ID: 1913664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors.
    Braunschweiger PG; Johnson CS; Kumar N; Ord V; Furmanski P
    Cancer Res; 1988 Nov; 48(21):6011-6. PubMed ID: 3262418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
    Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
    Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
    Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors.
    Constantinidis I; Braunschweiger PG; Wehrle JP; Kumar N; Johnson CS; Furmanski P; Glickson JD
    Cancer Res; 1989 Nov; 49(22):6379-82. PubMed ID: 2804984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of interleukin 1 alpha in combination with hyperthermia.
    Song CW; Lin JC; Lyons JC
    Cancer Res; 1993 Jan; 53(2):324-8. PubMed ID: 8417825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.
    Chang MJ; Modzelewski RA; Russell DM; Johnson CS
    Cancer Res; 1996 Feb; 56(4):886-91. PubMed ID: 8631029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
    Johnson CS; Chang MJ; Yu WD; Modzelewski RA; Grandis JR; Vlock DR; Furmanski P
    Cancer Chemother Pharmacol; 1993; 32(5):339-46. PubMed ID: 8339383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
    Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
    Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
    Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.